Development of an Interferon-γ ELISPOT Assay to Assess Varicella-Zoster Virus-Specific Cell-Mediated Immunity in Children.
Han Mi Seon MS, Choi Eun Hwa EH
Cell-mediated immunity (CMI) is fundamental in the prevention and control of varicella-zoster virus (VZV) infection and reactivation. This study aimed to develop and optimize a standardized interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay to precisely quantify VZV-specific T-cell responses in pediatric populations. Peripheral blood mononuclear cells (PBMCs) were isolated from the whole blood of seven healthy adult and six pediatric donors, collected in heparinized tubes. An ultraviolet (UV)-inactivated varicella vaccine was utilized as the VZV-specific antigen. PBMCs were incubated on 96-well plates pre-coated with anti-human IFN-γ monoclonal antibodies. Secreted IFN-γ was detected using biotinylated anti-human IFN-γ antibodies, streptavidin-horseradish peroxidase, and chromogen substrate. Spot-forming cells (SFCs) were enumerated using and ImmunoSpot Image Analyzer system. Various experimental parameters, including antigen dilution, PBMC density, and the impact of cryopreservation, were evaluated in triplicate. UV irradiation for 60 minutes completely abolished VZV replication while preserving stimulatory activity equivalent to that of the live-attenuated virus. Optimal VZV-specific responses were achieved at an antigen dilution of 1:25. Titration of PBMC concentrations demonstrated that a density of 1 × 10⁶ cells/well yielded the most robust and consistent SFC counts. Furthermore, IFN-γ ELISPOT responses from cryopreserved PBMCs were equivalent to those from freshly isolated cells, confirming the reliability of using frozen samples. In the pediatric cohort, the assay successfully detected VZV-specific CMI by utilizing a higher density of PBMCs per mL of whole blood. The optimized IFN-γ ELISPOT assay established in this study provides a sensitive, reproducible, and safe method for monitoring VZV-specific CMI. This standardized protocol is well-suited for evaluating vaccine efficacy and assessing disease susceptibility in immunocompromised children in clinical settings.